Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec
Pediatrics International · 2025-01 · 67 (1)
DOI: 10.1111/ped.70019 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatrics International, online erschienen am 14.05.2025. Verfasst von Akihisa Horigome und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Biological Products, Genetic Therapy, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Spinal muscular atrophy (SMA) is a recessively inherited neurological disease resulting in motor neuron disorder. Onasemnogene abeparvovec is a gene replacement therapy used to treat patients with SMA. Cardiac toxicity was observed in animal studies on this therapy, and elevated cardiac troponin I levels were observed in clinical trials; however, the clinical importance of these findings is unknown. Therefore, this study aimed to reveal the cardiac toxicity of onasemnogene abeparvovec through careful investigation of cardiac function using cardiac strain analysis, which can detect early subtle abnormalities.
Methods
This study included patients with SMA treated with onasemnogene abeparvovec between June 2020 and November 2020. Echocardiography, including peak global longitudinal strain (GLS), and other laboratory test results were evaluated.
Results
Case 1 showed a relative GLS decrease of 14.5% compared with that at the baseline (GLS reduction from −22.1% to −18.9%), elevation of N‐terminal prohormone B‐type natriuretic peptide levels from 227 pg/mL to 494 pg/mL, and elevated liver enzyme concentrations after gene replacement therapy without reduction of the left ventricular ejection fraction.
Conclusions
Subclinical myocardial dysfunction after infusion of onasemnogene abeparvovec was suggested by careful investigation of cardiac function. Cardiac toxicity may correlate with liver impairment following gene replacement therapy. Long‐term studies that allow for a higher number of patients and more extended observation periods should be conducted to confirm the cardiac toxicity of onasemnogene abeparvovec.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Genomic Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan.
ORCID-Profile: Akihisa Horigome, Katsuyoshi Shimozawa
Zitieren
APA
Horigome, A., Takasago, S., Arakawa, R., Shimozawa, K., Kaneshige, M., Goishi, K., Uryu, H., Yamanaka, J., Shichino, H., & Mizukami, A. (2025). Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70019
Vancouver
Horigome A, Takasago S, Arakawa R, Shimozawa K, Kaneshige M, Goishi K, et al. Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec. Pediatrics International. 2025;67(1). doi:10.1111/ped.70019
BibTeX
@article{Horigome2025,
author = {Horigome, Akihisa and Takasago, Satoshi and Arakawa, Reiko and Shimozawa, Katsuyoshi and Kaneshige, Masao and Goishi, Keiji and Uryu, Hideko and Yamanaka, Junko and Shichino, Hiroyuki and Mizukami, Ayumi},
title = {Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec},
journal = {Pediatrics International},
year = {2025},
volume = {67},
number = {1},
doi = {10.1111/ped.70019}
}
EUVIMED